Is a complete AVIR research report available?

No complete published report is available for Atea Pharmaceuticals, Inc. (AVIR) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · USD

$4.74

+0.12 (+2.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AVIR analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	379.3M
Net income (ttm)	-169.5M
EPS (ttm)	-$2.12
Shares out	80M
Volume	563,399
Beta	0.32
Price target	$8.67	+82.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -169.5M
EPS (ttm): -$2.12
Market cap: 379.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AVIR indicators

Market & fundamental data

Available fields

183

Groups with data

Currency

USD

Showing 183 of 183 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001593899
Company name	Atea Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	04683R106
Employees	55
Employees Change	-1%
Employees Change Percent	-1.79
Enterprise value	$124M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-10-30
Isin	US04683R1068
Last refreshed	2026-07-31
Market cap	$379.3M
Market cap category	Small-Cap
Price	$4.74
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	AVIR
Website	https://ateapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-44.69%
FCF yield	-38.98%
P/B ratio	1.62x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-159.3M
Net Income	$-169.5M
Net Income Growth Years	1%
Profit Per Employee	$-3.1M
ROA	-33.52
Roa5y	-11.07
ROCE	-81.24
ROE	-52.58
Roe5y	-19.77
ROIC	-36.64

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	24.76%
Cagr3y	11.71%
Cagr5y	-27.92%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$267.1M
Cash	$256M
Current Assets	$263.2M
Current Liabilities	$33.4M
Debt	$634,000
Debt Equity	$0
Equity	$233.7M
Liabilities	$33.4M
Long Term Assets	$3.9M
Long Term Liabilities	$0
Net Cash	$255.4M
Net Cash By Market Cap	$67.32
Net Cash Growth	-39.77%
Net Debt Equity	$-1.09
Tangible Book Value	$233.7M
Tangible Book Value Per Share	$2.92
WACC	5.98

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.89
Net Working Capital	$-25.5M
Quick ratio	7.67
Working Capital	$229.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.4%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	24.74%
200-day SMA	4.34
3Y total return	39.41%
50-day SMA	4.57
50-day SMA vs 200-day SMA	50over200
5Y total return	-80.53%
All Time High	94.17
All Time High Change	-94.97%
All Time High Date	2021-02-11
All Time Low	2.46
All Time Low Change	93.08%
All Time Low Date	2025-05-15
ATR	0.29
Beta	0.32
Beta1y	0.57
Beta2y	0.74
Ch YTD	32.77
High	4.95
High52	6.45
High52 Date	2026-03-10
High52ch	-26.51%
Low	4.53
Low52	2.78
Low52 Date	2025-10-02
Low52ch	70.5%
Ma50ch	3.77%
Price vs 200-day SMA	9.12%
RSI	50.85
RSI Monthly	52.51
RSI Weekly	51.84
Sharpe ratio	0.62x
Sortino ratio	1
Total Return	5.4%
Tr YTD	32.77
Tr1m	2.82%
Tr1w	-0.21%
Tr3m	-12.71%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	3
Analyst Price Target Top	$8
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.56
Operating Income	$-189.6M
Price target	$8.67
Price Target Change	$82.91
Price Target Change Top	$68.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60,052,321%
Float Percent	75.04%
Shares Insiders	16.14%
Shares Institutions	67.98%
Shares Out	80,027,099
Shares Qo Q	1.37%
Shares Yo Y	-5.4%
Short Float	12.92%
Short Ratio	20.21
Short Shares	9.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-165.4M
Adjusted OCF	-165,357,000
Average Volume	378,295.35x
Bv Per Share	2.92
Ch1m	2.82
Ch1w	-0.21
Ch1y	24.74
Ch3m	-12.71
Ch3y	39.41
Ch5y	-80.53
Ch6m	21.23
Change	2.6%
Change From Open	3.04
Close	4.62
Days Gap	-0.43
Depreciation Amortization	416,000
Dollar Volume	2,670,511.3
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-189.9M
EBITDA	$-189.4M
EPS	$-2.12
F Score	1
FCF	$-147.9M
FCF EV Yield	-119.28x
FCF Per Share	$-1.85
Financing CF	-25,141,000
Fiscal Year End	December
Founded	2,012
Income Tax	$-6.3M
Investing CF	132,923,000
Ipr	-80.25
Iprfo	-82.46
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-05
Ma150	4.74
Ma150ch	0.04%
Ma20	4.8
Ma20ch	-1.19%
Net CF	-40,077,000
Next Earnings Date	2026-08-10
Open	4.6
Optionable	Yes
Position In Range	50
Post Close	4.74
Postmarket Change Percent	0.84
Postmarket Price	$4.78
Ppne	831,000
Price Date	2026-07-30
Ptbv Ratio	1.62
Relative Volume	1.49x
Share Based Comp	17,498,000
Tr6m	21.23%
Us State	Massachusetts
Volume	563,399

Atea Pharmaceuticals, Inc. (AVIR)

Coverage state: Market snapshot only — no published research

Generate the first AVIR analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AVIR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AVIR indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AVIR

Frequently asked questions